Japan's MHLW Calls Attention To Liver Failure Associated With Tamiflu
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labor and Welfare reported cases of fulminate hepatic failure associated with flu drug Tamiflu. According to Chugai Pharmaceuticals, Tamiflu's importer and distributor in Japan, two deaths from fulminate hepatic failure after taking Tamiflu were reported since the market launch of the drug in 2001. MHLW also requested a warning label change to Tamiflu. (Click here for more - Japanese language) "MHLW Calls Attentions To Fulminate Hepatic Failure Caused By Taking Tamiflu" - Yomiuri News (3/1/08)
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.